AJMC January 23, 2025
Key Takeaways
- Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%.
- CMS increased biosimilar reimbursement to ASP plus 8% of the originator’s ASP, effective until 2027.
- Competitive pricing strategies include significant discounts for biosimilars, with some offering up to 86% lower WACs.
- New biosimilars for aflibercept, ustekinumab, and denosumab are anticipated to impact market dynamics.
Samsung Bioepis’ Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly.
Oncology, ophthalmology, and pegfilgrastim biosimilars reached an average biosimilar market share of 81% by 5 years post launch, according to a Samsung Bioepis’ First Quarter (Q1)...
Today's Sponsors
Today's Sponsor